Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )
ClinicalTrials.gov Identifier:
NCT01915225
First received: July 31, 2013
Last updated: December 1, 2016
Last verified: October 2016
  Purpose

Background:

- Recent advances in cancer research have led to new therapies to treat the disease. It is important to continue these advances and discover new ones. To do that, researchers need tissue samples from solid tumors. This study will collect such samples from people already scheduled to have a procedure at the National Institutes of Health Clinical Center (NIHCC).

Objectives:

- To collect tissue samples for use in studying new ways to treat tumors.

Eligibility:

- Adults 18 years and older, with a precancerous or cancerous solid tumor who are scheduled to have surgery or a biopsy at the NIHCC.

Design:

  • Before their procedure, participants will have a small blood sample taken.
  • Some participants will undergo leukapheresis. In this procedure, blood is removed through a tube in one arm and circulated through a machine that removes white blood cells. The blood, minus the white blood cells, is returned through a tube in the other arm. The procedure takes 3 4 hours.
  • For all participants, during the surgery or biopsy, pieces of the tumor and pieces of normal tissue near it will be removed for this study. The rest of the tumor or precancerous growth will be sent to a lab for analysis.
  • Participants will return to the clinic about 6 weeks after the operation for a routine checkup. Some may have to return for additional follow-up.

Condition
Colorectal Neoplasms
Gastric Neoplasms
Cholangiocarcinoma
Bile Duct Cancer
Pancreas Cancer

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Tumor, Normal Tissue and Specimens From Patients Undergoing Evaluation or Surgical Resection of Solid Tumors

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:
  • To collect biologic samples from patients undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors for the purpose ofidentifying novel molecular and biologictherapeutic targets [ Time Frame: 10 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To collect detailed history, demographic, treatment data, and perioperative findings in order to categorize and track the specific procedures and outcomes [ Time Frame: 10 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 1000
Study Start Date: July 2013
Estimated Study Completion Date: June 2024
Estimated Primary Completion Date: June 2023 (Final data collection date for primary outcome measure)
Detailed Description:

BACKGROUND:

  • Recent advances and insights into the molecular pathogenesis of cancer have led to the development of novel molecular and biologic targeted therapies for the treatment of advanced cancer patients. A critical challenge in extending these studies involves the identification and validation of new therapeutic targets for future cancer therapies.
  • As Surgical Oncologists at the NCI, we have an interest in identifying novel molecular and biologic targets to facilitate the development of future cancer therapies. In addition, we have the primary responsibility for providing surgical consultative services to the NIH. As such, we are uniquely positioned to acquire and perform important studies on solid tumor tissue to help identify therapeutic targets that may have significant clinical ramifications.

OBJECTIVES:

- Primary Objective: To collect biologic samples from patients undergoing diagnostic, preventative, or therapeutic interventions for premalignant, primary or metastatic solid tumors for the purpose of identifying novel molecular and biologic therapeutic targets

ELIGIBILITY:

  • Patients greater than or equal to 18 years of age with radiographic evidence or clinical suspicion of, genetic predisposition for, biochemical evidence of, or histologically/cytologically proven solid neoplasms who require diagnostic, preventative, or therapeutic intervention as a part of the diagnosis and /or treatment and/or follow up for their neoplasm
  • Patients without solid tumors in whom a diagnostic, preventative, or therapeutic intervention is being performed, but for whom surgical quality and safety outcomes data are generated.
  • Patients should have laboratory and physical examination parameters within acceptable limits by standard of practice guidelines prior to planned intervention

DESIGN:

  • A tissue acquisition trial in which tissues will be obtained at the time of intervention
  • Tissue and blood will be processed at the time of collection, transferred to the Clinical Pharmacology program (CPP) for further processing.
  • No investigational therapy will be given.
  • It is anticipated that 1000 patients will be enrolled over a period of 10 years
  Eligibility

Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA
  • Patients must be greater than or equal to 18 years of age.
  • Patients who have a premalignant, primary or metastatic solid tumors based upon either radiographic or clinical suspicion, biochemical testing, a genetic predisposition, or histological/cytological analysis that requires surgery or biopsy as part of the diagnosis, prevention, treatment and/or follow up
  • Patients without solid tumors in whom a diagnostic, preventative, or therapeutic intervention is being performed, but for whom surgical quality and safety outcomes data are generated.
  • Patients should have laboratory and physical examination parameters within acceptable limits prior to biopsy or surgery.
  • Patients must be planning to undergo surgery or biopsy as part of their normal treatment plan.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01915225

Contacts
Contact: Marcia Mulquin, R.N. (301) 435-5613 mmulquin@mail.nih.gov
Contact: Jeremy L Davis, M.D. (301) 402-9284 jeremy.davis@nih.gov

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact NCI/Surgery Branch Recruitment Center    866-820-4505    ncisbirc@mail.nih.gov   
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Principal Investigator: Jeremy L Davis, M.D. National Cancer Institute (NCI)
  More Information

Additional Information:
Publications:
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT01915225     History of Changes
Other Study ID Numbers: 130176  13-C-0176 
Study First Received: July 31, 2013
Last Updated: December 1, 2016
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Tissue Procurement
Surgery
Metastasectomy

Additional relevant MeSH terms:
Bile Duct Neoplasms
Neoplasms
Cholangiocarcinoma
Colorectal Neoplasms
Pancreatic Neoplasms
Stomach Neoplasms
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Biliary Tract Neoplasms
Bile Duct Diseases
Biliary Tract Diseases
Endocrine Gland Neoplasms
Pancreatic Diseases
Endocrine System Diseases
Stomach Diseases

ClinicalTrials.gov processed this record on December 05, 2016